Deutsche Bank Aktiengesellschaft Reiterates Sell Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “sell” rating reissued by research analysts at Deutsche Bank Aktiengesellschaft in a report released on Wednesday,London Stock Exchange reports. They currently have a £115 price objective on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective suggests a potential downside of 4.45% from the stock’s previous close.

Other research analysts also recently issued reports about the company. Jefferies Financial Group reiterated a “buy” rating and issued a £175 target price on shares of AstraZeneca in a research note on Monday. Citigroup lifted their price objective on AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research note on Tuesday, July 28th. Finally, Berenberg Bank reaffirmed a “buy” rating and issued a £160 price target on shares of AstraZeneca in a report on Tuesday, July 28th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of £152.17.

AstraZeneca Price Performance

LON:AZN traded up GBX 296 during trading hours on Wednesday, hitting £120.36. 1,763,656,500 shares of the stock were exchanged, compared to its average volume of 40,949,230. AstraZeneca has a 52-week low of £107.84 and a 52-week high of £157.32. The company has a market cap of £186.66 billion, a P/E ratio of 18.02, a P/E/G ratio of 0.86 and a beta of 0.23. The firm’s fifty day moving average price is £133.11 and its 200 day moving average price is £139.88. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 64.10.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.